Germany proclaims "best ever" mammo screening
This article was originally published in Clinica
Executive Summary
Never before has Germany had such a high-quality and reliable breast screening programme for early cancer detection." So said Andreas Kohler, head of the association of statutory sickness funds (KBV), at a conference this week in Berlin. Sharing the podium was health minister Ulla Schmidt, who said that more than 1.4 million women in Germany have so far made use of the reimbursed breast cancer diagnosis facility that allows women aged 50-69 to be screened every two years. The aim of the programme is to offer early, appropriate and targeted therapy to the 57,000 women in Germany who contract breast cancer every year, and thereby cut mortality rates. Some 17,500 women die from the disease every year in Germany. The programme, which covers 10 million women, offers dual checking by specialists, and subjects the mammography equipment to safety checks daily. The programme costs the sickness funds euro250-300m ($380-450m) per year, but is seen by minister Schmidt as money well spent.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.